Watson buys Teva products for $36 million
This article was originally published in Scrip
Executive Summary
Watson Pharmaceuticals is paying $36 million up front to buy 17 generic products from Teva Pharmaceutical Industries. Teva is divesting the products as part of its proposed acquisition of Barr Pharmaceuticals.